<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094883</url>
  </required_header>
  <id_info>
    <org_study_id>19-1145</org_study_id>
    <nct_id>NCT04094883</nct_id>
  </id_info>
  <brief_title>Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine</brief_title>
  <acronym>4CMenB</acronym>
  <official_title>Institute for Global Health and Infectious Diseases (IGHID) 11911 - Cross-reactive N. Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North Carolina Translational and Clinical Sciences Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether the group B meningitis vaccine (brand name&#xD;
      Bexsero™) induces immune responses against the bacteria that causes gonorrhea.&#xD;
&#xD;
      Participants: Approximately 15 Individuals who are 18-25 years of age that are not pregnant,&#xD;
      HIV negative, have no history of congenital immunologic disorder, and are not taking immune&#xD;
      suppressive medications will be enrolled on this study at a single site, University of North&#xD;
      Carolina at Chapel Hill (UNC-CH).&#xD;
&#xD;
      Procedures (methods): Participants will receive two-doses of an FDA-approved vaccine that&#xD;
      provides protection from N. meningitidis infection according to the recommended dosing&#xD;
      schedule. The first vaccine dose will be given to participants at the entry visit and the&#xD;
      second vaccine dose will be given to participants at the week 5 visit. The participants will&#xD;
      provide samples of blood as well as mucosal surface derived samples (urine and/or swabs) at&#xD;
      four separate visits (entry, week 5, week 6, and week 7).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single center, single arm, interventional pilot study in which participants&#xD;
      will receive two-doses of the 4CMenB vaccine according to the recommended administration&#xD;
      schedule and will provide blood, pharyngeal swabs, and urine or self-collected vaginal swabs&#xD;
      at each of four study visits.&#xD;
&#xD;
      The study population will include 15 individuals aged 18-25 years with no contraindication to&#xD;
      vaccination and no known immune compromising medical condition or medication.&#xD;
&#xD;
      Participants will be seen for informed consent and eligibility screening. Enrolled&#xD;
      participants will be given 1 dose of 4CMenB at enrollment and a second dose at week 5.&#xD;
      Participants will be seen at entry, weeks 5, 6, and 7 for blood collection, pharyngeal swabs,&#xD;
      and provide urine (male participants) or self-collected vaginal swabs collected for secondary&#xD;
      screening and baseline immunologic testing.&#xD;
&#xD;
      Screening Evaluations Screening evaluations include: medical history, medication history&#xD;
      within the past 60 days, vital signs, targeted physical exam, and pregnancy test for female&#xD;
      participants of child bearing potential). Screening visit must be conducted no greater than&#xD;
      30 days prior to enrollment visit. The screening evaluation and enrollment visit can all&#xD;
      occur on the same day. Participants may be re-screened one time.&#xD;
&#xD;
      Entry Evaluations&#xD;
&#xD;
      Entry evaluations will be collected PRIOR to phlebotomy, specimen collection, and vaccine&#xD;
      administration:&#xD;
&#xD;
      Acute Illness Assessment will be completed before phlebotomy, specimen collection, and&#xD;
      vaccine administration. Participants who have an acute illness may be rescheduled for their&#xD;
      phlebotomy, specimen collection, and vaccine within their screening visit window.&#xD;
&#xD;
      Update medical history and concomitant medications. Conduct a targeted physical exam and&#xD;
      collect vital signs [heart rate (HR), blood pressure (BP), oral temperature (Temp),&#xD;
      respiration rate (RR), and weight] prior to phlebotomy to collect up to 60 mL of blood,&#xD;
      specimen collection, and vaccine administration.&#xD;
&#xD;
      For females of reproductive potential, negative urine pregnancy testing results must be&#xD;
      available before phlebotomy, specimen collection, and vaccine administration.&#xD;
&#xD;
      Samples to be stored for immunologic testing will be batch run at the end of the study:&#xD;
&#xD;
      pharyngeal swabs, urine sample (from male participants), self-collected vaginal swabs (from&#xD;
      female participants), serum, and peripheral blood mononuclear cells (PBMC).&#xD;
&#xD;
      Post-Entry Evaluations&#xD;
&#xD;
      Week 5 Evaluations:&#xD;
&#xD;
      Acute Illness Assessment will be completed before phlebotomy, specimen collection, and&#xD;
      vaccine administration. Participants who have an acute illness or who have taken exclusionary&#xD;
      anticoagulant medications may be rescheduled for their vaccine within their screening visit&#xD;
      window.&#xD;
&#xD;
      Update medical history and concomitant medications before phlebotomy and vaccine&#xD;
      administration. Conduct a targeted physical exam and collect vital signs (HR, BP, Temp, RR)&#xD;
      before phlebotomy to collect up to 60 mL of blood, specimen collection, and vaccine&#xD;
      administration.&#xD;
&#xD;
      For females of reproductive potential, negative urine pregnancy testing results must be&#xD;
      available before phlebotomy, specimen collection, and vaccine administration.&#xD;
&#xD;
      Week 5 laboratory evaluations will be collected PRIOR to vaccine administration:&#xD;
&#xD;
      Samples to be stored for immunologic testing will be batch run at the end of the study:&#xD;
&#xD;
      pharyngeal swabs, urine sample (from male participants), self-collected vaginal swabs (from&#xD;
      female participants), serum, and PBMC.&#xD;
&#xD;
      Week 6 and Week 7 Evaluations:&#xD;
&#xD;
      Update medical history and concomitant medications prior to phlebotomy to collect up to 60 mL&#xD;
      of blood and specimen collection.&#xD;
&#xD;
      Samples to be stored for immunologic testing will be batch run at the end of the study:&#xD;
&#xD;
      pharyngeal swabs, urine sample (from male participants), self-collected vaginal swabs (from&#xD;
      female participants), serum, and PBMC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will receive the group B meningitis vaccine (brand name Bexsero™).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin G (IgG) Concentrations After Immunization</measure>
    <time_frame>pre-vaccination at entry visit (prior to first vaccination, Day 0) and week 7 visit (2 weeks after second vaccination)</time_frame>
    <description>The change in concentrations presented as the difference in geometric mean concentration in human serum of IgG binding to N. gonorrhoeae strain FA1090 surface antigens Outer-membrane vesicles (OMV) determined by ELISA in serum from entry visit and week 7 visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin M (IgM) Concentrations After Immunization</measure>
    <time_frame>pre-vaccination at entry visit (prior to first vaccination, Day 0) and week 7 visit (2 weeks after second vaccination)</time_frame>
    <description>The change in concentrations presented as the difference in geometric mean concentration in human serum of IgM binding to N. gonorrhoeae strain FA1090 surface antigens (Outer-membrane vesicles) determined by ELISA in serum from entry visit and week 7 visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin A (IgA ) Concentrations After Immunization</measure>
    <time_frame>pre-vaccination at entry visit (prior to first vaccination, Day 0) and week 7 visit (2 weeks after second vaccination)</time_frame>
    <description>The change in concentrations presented as the difference in geometric mean concentration in human serum of IgA binding to N. gonorrhoeae strain FA1090 surface antigens (Outer-membrane vesicles) determined by ELISA in serum from entry visit and week 7 visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Proportion of Cluster of Differentiation 4 Positive (CD4+) T Cells Expressing at Least Two Different Activation Markers After Immunization</measure>
    <time_frame>pre-vaccination at entry visit (prior to first vaccination, Day 0) and week 7 visit (2 weeks after second vaccination)</time_frame>
    <description>Flow cytometry used to measure the number of CD4+ lymphocytes expressing Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), Interleukin-2 (IL-2), and Cluster of Differentiation 107a (CD107a) after in vitro stimulation with N. gonorrhoeae strain FA1090 Outer-membrane vesicles in circulating peripheral blood mononuclear cells (PBMC). The frequency of CD4+ T cells expressing at least two activation markers will be expressed as a proportion of total CD4+ lymphocytes. The change in frequency will be presented as the difference between frequency of cells measured at entry visit and at week 7 visit.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Neisseria Gonorrhoeae Infection</condition>
  <arm_group>
    <arm_group_label>4CMenB Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Group B Vaccine</intervention_name>
    <description>All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.</description>
    <arm_group_label>4CMenB Vaccine</arm_group_label>
    <other_name>Bexsero</other_name>
    <other_name>4-component Neisseria meningitidis group B vaccine</other_name>
    <other_name>4CMenB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and give informed consent&#xD;
&#xD;
          2. Willingness to undergo all study procedures.&#xD;
&#xD;
          3. Males or females between the ages of 18 to 25 at screening (inclusive).&#xD;
&#xD;
          4. Good health, as determined by medical history and targeted physical exam.&#xD;
&#xD;
          5. Participants agree to abstain from vaccines from study entry to 30 days after receipt&#xD;
             of the second 4CMenB vaccine.&#xD;
&#xD;
          6. Female participants of child bearing potential must have a negative urine pregnancy&#xD;
             test at the screening visit, and prior to receipt of vaccines at study entry and week&#xD;
             5 visits. Self-reported history is acceptable documentation of hysterectomy, bilateral&#xD;
             oophorectomy, tubal ligation, or tubal micro-inserts which eliminate child bearing&#xD;
             potential of participant. If participating in sexual activity that could lead to&#xD;
             pregnancy, women must agree to use a form of contraceptive until 28 days after&#xD;
             completion of the vaccine series. At least one of the following methods must be used&#xD;
             appropriately: Condoms (male) with or without spermicidal agent, Diaphragm or cervical&#xD;
             cap with spermicide, Intrauterine device (IUD), or Hormone-based contraceptive.&#xD;
             Self-report of a monogamous male partner who has a vasectomy is also acceptable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy/sensitivity or any hypersensitivity to latex or any of the components of&#xD;
             the study product or its formulation (see section 5.2 for a list of components).&#xD;
&#xD;
          2. Participants who have received any vaccine directed against N. meningitidis serogroup&#xD;
             B&#xD;
&#xD;
          3. Serious illness or injury requiring hospitalization within 21 days prior to study&#xD;
             entry.&#xD;
&#xD;
          4. Current or prior history of a medical condition resulting in impaired immunity (such&#xD;
             as HIV infection, inborn or acquired immunodeficiency syndromes, all cancers including&#xD;
             leukemia or lymphoma, or the of use antineoplastic drugs or radiation treatment).&#xD;
&#xD;
          5. Known active infection with HIV, Hepatitis C Virus (HCV ), or Hepatitis B Virus (HBV).&#xD;
             This information will be obtained verbally from the participant.&#xD;
&#xD;
          6. History of excessive alcohol consumption, drug abuse, psychiatric conditions, social&#xD;
             conditions or occupational conditions that in the opinion of the investigator would&#xD;
             preclude compliance with the study.&#xD;
&#xD;
          7. Hemophilia or other bleeding diatheses.&#xD;
&#xD;
          8. Receipt of anticoagulants (aspirin or nonsteroidal anti-inflammatory drugs (NSAIDS)&#xD;
             are acceptable) within 14 days prior to study entry.&#xD;
&#xD;
          9. Autoimmune disorders; mild autoimmune disorders, such as eczema, are not exclusionary&#xD;
             and will be determined by the investigator.&#xD;
&#xD;
         10. Use of any systemic immunomodulatory treatment, systemic corticosteroids, (inhaled and&#xD;
             topical corticosteroids acceptable), investigational products, interleukins,&#xD;
             interferons, growth factors, or intravenous immunoglobulin (IVIG) within 45 days prior&#xD;
             to study entry.&#xD;
&#xD;
         11. Pregnant women and nursing mothers or women who are planning to become pregnant or&#xD;
             breastfeed within 28 days after receipt of their second 4CMenB vaccine.&#xD;
&#xD;
         12. Have received any licensed vaccine within 30 days prior to study vaccination.&#xD;
&#xD;
         13. Have donated blood or blood products within 30 days before study vaccination, plan to&#xD;
             donate blood at any time during the study and up to 30 days after the last blood draw.&#xD;
&#xD;
         14. Any condition in the opinion of the investigator that would interfere with the proper&#xD;
             conduct of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Duncan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC-Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina Health Care</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <results_first_submitted>June 24, 2021</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2021</results_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neisseria gonorrhoeae</keyword>
  <keyword>Cross-reactive</keyword>
  <keyword>Immune</keyword>
  <keyword>Responses</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gonorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual data that supports the results will be shared beginning 12 to 24 months following publication provided the investigator/researcher who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>12-24 months after publication</ipd_time_frame>
    <ipd_access_criteria>Other investigators/researchers who propose to use the individual participant data (IPD) from this study will need to have approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and execute a data use/sharing agreement with UNC.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT04094883/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT04094883/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>4CMenB Vaccine</title>
          <description>Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.&#xD;
Meningococcal Group B Vaccine: All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>4CMenB Vaccine</title>
          <description>Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.&#xD;
Meningococcal Group B Vaccine: All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin G (IgG) Concentrations After Immunization</title>
        <description>The change in concentrations presented as the difference in geometric mean concentration in human serum of IgG binding to N. gonorrhoeae strain FA1090 surface antigens Outer-membrane vesicles (OMV) determined by ELISA in serum from entry visit and week 7 visit</description>
        <time_frame>pre-vaccination at entry visit (prior to first vaccination, Day 0) and week 7 visit (2 weeks after second vaccination)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4CMenB Vaccine</title>
            <description>Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.&#xD;
Meningococcal Group B Vaccine: All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin G (IgG) Concentrations After Immunization</title>
          <description>The change in concentrations presented as the difference in geometric mean concentration in human serum of IgG binding to N. gonorrhoeae strain FA1090 surface antigens Outer-membrane vesicles (OMV) determined by ELISA in serum from entry visit and week 7 visit</description>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-N. gonorrhoeae OMV titer (dilution giving half maximal response) - Entry Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.57" lower_limit="38.7" upper_limit="97.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-N. gonorrhoeae OMV titer (dilution giving half maximal response) - Week 7 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.2" lower_limit="141.9" upper_limit="299.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin M (IgM) Concentrations After Immunization</title>
        <description>The change in concentrations presented as the difference in geometric mean concentration in human serum of IgM binding to N. gonorrhoeae strain FA1090 surface antigens (Outer-membrane vesicles) determined by ELISA in serum from entry visit and week 7 visit</description>
        <time_frame>pre-vaccination at entry visit (prior to first vaccination, Day 0) and week 7 visit (2 weeks after second vaccination)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4CMenB Vaccine</title>
            <description>Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.&#xD;
Meningococcal Group B Vaccine: All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin M (IgM) Concentrations After Immunization</title>
          <description>The change in concentrations presented as the difference in geometric mean concentration in human serum of IgM binding to N. gonorrhoeae strain FA1090 surface antigens (Outer-membrane vesicles) determined by ELISA in serum from entry visit and week 7 visit</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-N. gonorrhoeae OMV titer (dilution giving half maximal response) - Entry Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.89" lower_limit="58.96" upper_limit="128.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-N. gonorrhoeae OMV titer (dilution giving half maximal response) - Week 7 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.84" lower_limit="57.34" upper_limit="122.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin A (IgA ) Concentrations After Immunization</title>
        <description>The change in concentrations presented as the difference in geometric mean concentration in human serum of IgA binding to N. gonorrhoeae strain FA1090 surface antigens (Outer-membrane vesicles) determined by ELISA in serum from entry visit and week 7 visit</description>
        <time_frame>pre-vaccination at entry visit (prior to first vaccination, Day 0) and week 7 visit (2 weeks after second vaccination)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4CMenB Vaccine</title>
            <description>Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.&#xD;
Meningococcal Group B Vaccine: All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin A (IgA ) Concentrations After Immunization</title>
          <description>The change in concentrations presented as the difference in geometric mean concentration in human serum of IgA binding to N. gonorrhoeae strain FA1090 surface antigens (Outer-membrane vesicles) determined by ELISA in serum from entry visit and week 7 visit</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-N. gonorrhoeae OMV titer (dilution giving half maximal response) - Entry Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.689" lower_limit="2.155" upper_limit="6.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-N. gonorrhoeae OMV titer (dilution giving half maximal response) - Week 7 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.725" lower_limit="3.044" upper_limit="7.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Proportion of Cluster of Differentiation 4 Positive (CD4+) T Cells Expressing at Least Two Different Activation Markers After Immunization</title>
        <description>Flow cytometry used to measure the number of CD4+ lymphocytes expressing Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), Interleukin-2 (IL-2), and Cluster of Differentiation 107a (CD107a) after in vitro stimulation with N. gonorrhoeae strain FA1090 Outer-membrane vesicles in circulating peripheral blood mononuclear cells (PBMC). The frequency of CD4+ T cells expressing at least two activation markers will be expressed as a proportion of total CD4+ lymphocytes. The change in frequency will be presented as the difference between frequency of cells measured at entry visit and at week 7 visit.</description>
        <time_frame>pre-vaccination at entry visit (prior to first vaccination, Day 0) and week 7 visit (2 weeks after second vaccination)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4CMenB Vaccine</title>
            <description>Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.&#xD;
Meningococcal Group B Vaccine: All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Proportion of Cluster of Differentiation 4 Positive (CD4+) T Cells Expressing at Least Two Different Activation Markers After Immunization</title>
          <description>Flow cytometry used to measure the number of CD4+ lymphocytes expressing Interferon-gamma (IFN-g), Tumor Necrosis Factor-alpha (TNF-a), Interleukin-2 (IL-2), and Cluster of Differentiation 107a (CD107a) after in vitro stimulation with N. gonorrhoeae strain FA1090 Outer-membrane vesicles in circulating peripheral blood mononuclear cells (PBMC). The frequency of CD4+ T cells expressing at least two activation markers will be expressed as a proportion of total CD4+ lymphocytes. The change in frequency will be presented as the difference between frequency of cells measured at entry visit and at week 7 visit.</description>
          <units>proportion CD4 cells</units>
          <param>Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>proportion of CD4+ positive lymphocytes expressing least two activation markers -Entry Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002750" lower_limit="0.001222" upper_limit="0.004279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>proportion of CD4+ positive lymphocytes expressing least two activation markers - week 7 Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003058" lower_limit="0.002552" upper_limit="0.003564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of Informed Consent until study completion, a total of up to 26 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>4CMenB Vaccine</title>
          <description>Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.&#xD;
Meningococcal Group B Vaccine: All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site (left deltoid) pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site (left deltoid) tenderness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site (left deltoid) erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site (left deltoid) induration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Injection site (left deltoid) swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Subjective fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>cough and nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>wisdom teeth extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Duncan, MD, PhD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-966-2536</phone>
      <email>joseph_duncan@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

